Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | GCKR | Q14397 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20956389 | 1.00 | HSD11B1 (0.54) | HSD11B1KIF11GCKGCKRNR1H3 | |
| SCHEMBL19181908 | 1.00 | HSD11B1 (0.54) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL20956393 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL20956392 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| Hydrochloric Acid SCHEMBL19179710 | 0.98 | HSD11B1 (0.53) | HSD11B1KIF11GCKGCKRNR1H3 | |
| SCHEMBL10165226 | 0.88 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL13917764 | 0.85 | ALDH1A1 (0.48) | HSD11B1KIF11NPC1ALDH1A1MAPT | |
| SCHEMBL25753451 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL15459955 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL5530921 | 0.79 | MLYCD (0.52) | HSD11B1NR1H3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| EP-1917233-B1 | ANILINOHEXAFLUOROISOPROPANOL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1907357-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | HSD11B1 3134/4885KIF11 2817/4885GCK 338/4885 |
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HSD11B1 3406/4885KIF11 1876/4885GCK 1721/4885 |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | HSD11B1 3406/4885KIF11 1876/4885GCK 1721/4885 |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | HSD11B1 87/4885KIF11 3808/4885GCK 4037/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | HSD11B1 87/4885KIF11 3808/4885GCK 4037/4885 |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | HSD11B1 17/4885KIF11 2802/4885GCK 4597/4885 |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | ARSA, SULT2A1, SULT1A1 | HSD11B1 680/4885KIF11 4011/4885GCK 1515/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HSD11B1 762/4885KIF11 2128/4885GCK 50/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885KIF11 2061/4885GCK 972/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HSD11B1 3523/4885KIF11 1709/4885GCK 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.